Evidence map›Paper›PMID 40168129›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Signaling networks in cancer stromal senescent cells establish malignant microenvironment.

Yue Zhang, Teh-Wei Wang, Maho Tamatani, Xinyi Zeng, Lindo Nakamura, Satotaka Omori, Kiyoshi Yamaguchi, Seira Hatakeyama, Eigo Shimizu, Satoshi Yamazaki and 4 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yue Zhang *Division of Cancer Cell Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Teh-Wei Wang *Division of Cancer Cell Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Maho TamataniDivision of Cancer Cell Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Xinyi ZengDivision of Cancer Cell Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Lindo NakamuraDivision of Cancer Cell Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Satotaka OmoriDivision of Cancer Cell Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Kiyoshi YamaguchiDivision of Clinical Genome Research, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.ORCID 0000-0003-2113-4369
Seira HatakeyamaDivision of Clinical Genome Research, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Eigo ShimizuDivision of Health Medical Intelligence, Human Genome Center, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Satoshi YamazakiDivision of Cell Regulation, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Yoichi FurukawaDivision of Clinical Genome Research, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Seiya ImotoDivision of Health Medical Intelligence, Human Genome Center, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Yoshikazu JohmuraDivision of Cancer and Senescence Biology, Cancer Research Institute, Kanazawa University, Kanazawa 920-1192, Japan.
Makoto NakanishiDivision of Cancer Cell Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.ORCID 0000-0002-6707-3584

Funding

Japan Agency for Medical Research and Development (AMED) 214600040Japan Agency for Medical Research and Development (AMED) 21cm0106175Japan Agency for Medical Research and Development (AMED) 21gm5010001Japan Agency for Medical Research and Development (AMED) 21zf0127003MEXT | Japan Society for the Promotion of Science (JSPS) 19H05740MEXT | Japan Society for the Promotion of Science (JSPS) 20H00514MEXT | Japan Society for the Promotion of Science (JSPS) JP16H06148MEXT | Japan Society for the Promotion of Science (JSPS) JP16K15238MEXT | Japan Society for the Promotion of Science (JSPS) JP18H05026m
6 · The paper itself

Abstract

The tumor microenvironment (TME) encompasses various cell types, blood and lymphatic vessels, and noncellular constituents like extracellular matrix (ECM) and cytokines. These intricate interactions between cellular and noncellular components contribute to the development of a malignant TME, such as immunosuppressive, desmoplastic, angiogenic conditions, and the formation of a niche for cancer stem cells, but there is limited understanding of the specific subtypes of stromal cells involved in this process. Here, we utilized p16-Cre

Indexed as

Carcinoma, Pancreatic DuctalCellular SenescencePancreatic NeoplasmsSignal TransductionStromal CellsTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceNeoplastic Stem CellsNeovascularization, Pathologiccancer stromal cellspancreatic cancersenescence

Identifiers

PMID40168129
PMCPMC12002233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.